 |
|
|
| |
Genotypic and Phenotypic Weighted Optimized Background Therapy Susceptibility Scores Are Similarly Strong Predictors of Virologic Response <50 Copies/mL at Week 48 in MOTIVATE 1 and 2
|
| |
| |
Reported by Jules Levin
18th Intl HIV Drug Resistance Workshop
June 9-12
Ft Myers Florida
C Boucher1, JM Schapiro2, D Kuritzkes3, JM Llibre4, M Lewis5, P Simpson5, C Delogne5, V Sharma6, A Parliyan7, D Chapman7, M Perros5, H Valdez7,and M Westby51 Utrecht University, Utrecht, The Netherlands and Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands; 2 National Hemophilia Center, Tel Hashomer, Israel; 3 Brigham and Women's Hospital, Boston, MA, USA; 4 Hospital Germans Trias i Pujol, Badalona, Spain; 5 Pfizer Global R&D, Sandwich, UK; 6 Eliasses Group, Inc., Mansfield, MA, USA; 7Pfizer, Inc., New York, NY, USA
INTRODUCTION
The MOTIVATE 1 and 2 studies1,2 compared the efficacy and safety of maraviroc (MVC) once-daily (QD) or twice-daily (BID) to placebo (PBO) in treatment-experienced patients with CCR5-tropic (R5) HIV-1 infection at study screening. Both MVC and PBO were given with an investigator-selected optimized background therapy (OBT) of 3-6 agents, excluding darunavir, etravirine and raltegravir
Previous analyses in different subpopulations of the pooled MOTIVATE patient set have shown that virologic outcome is strongly correlated with a weighted drug sensitivity score (wOBTSS) for the OBT based on either phenotypic3 (p-wOBTSS)or genotypic4(g-wOBTSS) resistance testing
The purpose of this analysis was to compare directly the influence of p-wOBTSS and g-wOBTSS estimates of MOTIVATE OBT activity in the same study population
Reference
H-1221
Stokholm Sweden 2009
Presentation and Poster 112
Accessed May 2009
|
| |
|
|
|
|
|
